At the 2021 Fall Clinical Dermatology Conference, held virtually and from Las Vegas, pharmaceutical company Leo Pharma presented data from a new trial of its antibody treatment tralokinumab, sold under the brand name Adtralza, which is approved in the EU, the UK and Canada as a treatment for adults with moderate-to-severe atopic dermatitis.
The new results come from the phase III trial Ecztra 6, which has investigated the treatment in the younger segment of patients aged 12 to 17. The participants have received Adtralza over 16 weeks in one of two dosages, or a placebo substance.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.
More from MedWatch
In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.